Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies

Japanese guidelines for atopic dermatitis 2020

(2020) Norito Katoh et al.   ALLERGOLOGY INTERNATIONAL

The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases

(2020) Fatih A. Topal et al.   Current Opinion in Allergy and Clinical Immunology

Sleep disturbance and atopic dermatitis: A bidirectional relationship?

(2020) E.M.S. Xerfan et al.   MEDICAL HYPOTHESES

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

(2020) Kenji Kabashima et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-33/13 Axis and IL-4/31 Axis Play Distinct Roles in Inflammatory Process and Itch in Psoriasis and Atopic Dermatitis

(2020) Khaldon Bodoor et al.   Clinical Cosmetic and Investigational Dermatology

Immunotherapies in cutaneous pathologies: an overview

(2020) Audrey Baylet et al.   DRUG DISCOVERY TODAY

Association of Atopic Dermatitis With Sleep Quality in Children

(2019) Faustine D. Ramirez et al.   JAMA Pediatrics

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

(2019) G. Yosipovitch et al.   BRITISH JOURNAL OF DERMATOLOGY

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

(2019) Jonathan I. Silverberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Clinical practice guidelines for the management of atopic dermatitis 2018

(2019) Norito Katoh et al.   JOURNAL OF DERMATOLOGY

Epidemiology of atopic dermatitis in adults: Results from an international survey

(2018) S. Barbarot et al.   ALLERGY

The multidimensional burden of atopic dermatitis

(2018) Alanna C. Bridgman et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study

(2018) J.I. Silverberg et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods

(2018) L. Howells et al.   BRITISH JOURNAL OF DERMATOLOGY

Prurigo Nodularis and Its Management

(2018) Claudia Zeidler et al.   DERMATOLOGIC CLINICS

Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis

(2018) Chisa Nakashima et al.   EXPERIMENTAL DERMATOLOGY

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

(2018) Kenji Kabashima et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-31: A new key player in dermatology and beyond

(2018) Işın Sinem Bağci et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Atopic dermatitis

(2018) Stephan Weidinger et al.   Nature Reviews Disease Primers

Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

(2017) Thomas Ruzicka et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Insomnia Severity Index: Psychometric Indicators to Detect Insomnia Cases and Evaluate Treatment Response

(2017) Charles M. Morin et al.   SLEEP

The Patient-Oriented Eczema Measure in young children: responsiveness and minimal clinically important difference

(2016) D. M. Gaunt et al.   ALLERGY

IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function

(2016) Brijendra Singh et al.   PLoS One

What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study

(2015) Y.A. Leshem et al.   BRITISH JOURNAL OF DERMATOLOGY

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

(2015) O. Nemoto et al.   BRITISH JOURNAL OF DERMATOLOGY

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

(2015) M.K.A. Basra et al.   DERMATOLOGY

Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials

(2014) S Ständer et al.   ACTA DERMATO-VENEREOLOGICA

Visual Analogue Scale: Evaluation of the Instrument for the Assess­ment of Pruritus

(2013) A Reich et al.   ACTA DERMATO-VENEREOLOGICA

EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference

(2011) M. E. Schram et al.   ALLERGY

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three

(2009) Joseph A. Odhiambo et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY